Stock ZLAB N ZAI LAB LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Zai Lab Limited Share Price Mexican S.E.

Equities

ZLAB N

US98887Q1040

Pharmaceuticals

End-of-day quote Mexican S.E.
Other stock markets
 03:30:00 07/05/2024 am IST 		5-day change 1st Jan Change
273 MXN +0.74% Intraday chart for Zai Lab Limited -.--% -46.71%
27/06 Zai Lab Insider Sold Shares Worth $428,532, According to a Recent SEC Filing MT
20/06 Zai Lab Grants ADSs to Independent Directors Under Incentive Scheme MT

Financials

Sales 2024 * 393M 7.21B 32.76B Sales 2025 * 597M 10.93B 49.71B Capitalization 1.72B 31.48B 143B
Net income 2024 * -270M -4.95B -22.5B Net income 2025 * -157M -2.88B -13.08B EV / Sales 2024 * 3 x
Net cash position 2024 * 538M 9.86B 44.83B Net cash position 2025 * 275M 5.05B 22.95B EV / Sales 2025 * 2.42 x
P/E ratio 2024 *
-6.51 x
P/E ratio 2025 *
-11.2 x
Employees 2,175
Yield 2024 *
-
Yield 2025 *
-
Free-Float 9.91%
More Fundamentals * Assessed data

Chart Zai Lab Limited

Dynamic Chart

Latest news about Zai Lab Limited

Zai Lab Insider Sold Shares Worth $428,532, According to a Recent SEC Filing MT
Zai Lab Grants ADSs to Independent Directors Under Incentive Scheme MT
Asian Equities Traded in the US as American Depositary Receipts Trend Lower in Friday Trading MT
Transcript : Zai Lab Limited Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 01:20 PM
Zai Lab Limited Announces Executive Changes, Effective June 30, 2024 CI
Tech, Financial Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Sharply Lower Tuesday MT
Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Lower MT
Zai Lab Doses First Patient in a Phase 2 Clinical Trial of Plaque Psoriasis Treatment; Shares Rise MT
Zai Lab Limited Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis CI
Chinese Regulator Approves Zai Lab’s New Drug Application for Bacterial Pneumonia Drug MT
Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment MT
Zai Lab and Innoviva Specialty Therapeutics Announces NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China CI
Asian Equities Traded in the US as American Depositary Receipts Ease in Thursday Trading MT
Zai Lab's Supplemental Application for Autoimmune Disease Treatment Accepted by China Regulator MT
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy in China CI
More news

Latest transcript on Zai Lab Limited

Logo Zai Lab Limited
Zai Lab Limited Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 01:20 PM
More transcripts

Analyst Recommendations on Zai Lab Limited

Zai Lab Insider Sold Shares Worth $428,532, According to a Recent SEC Filing MT
Zai Lab Grants ADSs to Independent Directors Under Incentive Scheme MT
Zai Lab CEO, Others 'Do Not Anticipate' Selling Company Shares in Remainder of 2024 MT
Zai Lab Grants Share Options, Restricted Share Units to Eligible Personnel MT
Morgan Stanley Starts Coverage on Zai Lab with Overweight Rating, $47.50 Price Target MT
More recommendations

Press releases Zai Lab Limited

Zai Lab : Argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropath PU
Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D BU
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis BU
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China AQ
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China BU
More press releases

News in other languages on Zai Lab Limited

Hong Kong se convierte en el principal mercado para las cotizaciones chinas, según HKEX -- Market Talk
Tweede kwartaal Argen-x in teken lancering Vyvgart
Brussel fors hoger van start na Fed-rally op Wall Street
Argenx boekt eerste omzet met Vyvgart
EN DIRECTO DESDE LOS MERCADOS: Stellantis, Wendel, Soitec, Umanis, Tod's, Deutsche Telekom, Oracle, Rivian...
More news

Quotes and Performance

1 day+0.74%
3 months-46.71%
6 months-46.71%
Current year-46.71%
More quotes

Highs and lows

Current year
270.64
Extreme 270.64
273.00
1 year
270.64
Extreme 270.64
512.26
3 years
270.64
Extreme 270.64
2 446.85
5 years
270.64
Extreme 270.64
3 693.35
10 years
270.64
Extreme 270.64
3 693.35
More quotes

Managers and Directors - Zai Lab Limited

Managers TitleAgeSince
Ying Du CEO
 Chief Executive Officer 59 01/14/01
Ya jing Chen DFI
 Director of Finance/CFO 56 01/21/01
Joshua Smiley PSD
 President 54 01/22/01
Members of the board TitleAgeSince
John Diekman BRD
 Director/Board Member 81 01/17/01
Peter Wirth BRD
 Director/Board Member 73 01/17/01
Lonnie Moulder BRD
 Director/Board Member 66 01/19/01
More insiders

Company Profile

Zai Lab Ltd is a holding company mainly engaged in the biopharmaceutical field. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including oncology, autoimmune and infectious diseases fields. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include Niraparib (ZL-2306), ZL-2103, ZL-1101 and others.
Sector
Pharmaceuticals
Calendar
05/08/2024 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Zai Lab Limited

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
17.33 USD
Average target price
50.79 USD
Spread / Average Target
+193.10%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
CSL LIMITED Stock CSL Limited
+2.99% 95.18B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
-4.34% 37.55B
BIOGEN INC. Stock Biogen Inc.
-10.41% 33.75B
UCB Stock UCB
+75.79% 28.2B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-14.61% 15.63B
INCYTE CORPORATION Stock Incyte Corporation
-3.46% 13.63B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-12.31% 11.5B
ALTEOGEN INC. Stock ALTEOGEN Inc.
+184.77% 10.81B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-54.13% 9.23B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. ZLAB Stock
  4. ZLAB N Stock